Merus N.V. (MRUS): Price and Financial Metrics

Merus N.V. (MRUS): $40.31

0.96 (-2.33%)

POWR Rating

Component Grades








Add MRUS to Watchlist
Sign Up

Industry: Biotech




#269 of 363

in industry

MRUS Price/Volume Stats

Current price $40.31 52-week high $52.03
Prev. close $41.27 52-week low $18.21
Day low $39.70 Volume 820,134
Day high $41.11 Avg. volume 575,294
50-day MA $44.66 Dividend yield N/A
200-day MA $30.09 Market Cap 2.37B

MRUS Stock Price Chart Interactive Chart >

Merus N.V. (MRUS) Company Bio

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.

MRUS Latest News Stream

Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream

Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about MERUS NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 53% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 28, 2023

Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet

The mean of analysts' price targets for Merus N.V. (MRUS) points to an 87.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 12, 2023

Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade

Merus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 5, 2023

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-129 from ongoing expansion cohorts in non-small cell lung cancer (NSCLC) and in previous

Yahoo | December 3, 2023

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT - Poster presentation on MCLA-129 in previously treated HNSCC on Saturday, December 2 at 17:50 p.m. SGT - Investor call on Monday, November 27, 2023 8:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company deve

Yahoo | November 26, 2023

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo -8.18%
3-mo 25.42%
6-mo 92.69%
1-year 68.38%
3-year 79.00%
5-year 156.75%
YTD 46.58%
2023 77.76%
2022 -51.35%
2021 81.40%
2020 24.50%
2019 0.57%

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!